1. Home
  2. TNXP vs SVCC Comparison

TNXP vs SVCC Comparison

Compare TNXP & SVCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TNXP
  • SVCC
  • Stock Information
  • Founded
  • TNXP 2007
  • SVCC 2024
  • Country
  • TNXP United States
  • SVCC United States
  • Employees
  • TNXP N/A
  • SVCC N/A
  • Industry
  • TNXP Biotechnology: Pharmaceutical Preparations
  • SVCC
  • Sector
  • TNXP Health Care
  • SVCC
  • Exchange
  • TNXP Nasdaq
  • SVCC Nasdaq
  • Market Cap
  • TNXP 272.0M
  • SVCC 220.9M
  • IPO Year
  • TNXP N/A
  • SVCC 2025
  • Fundamental
  • Price
  • TNXP $49.73
  • SVCC $10.27
  • Analyst Decision
  • TNXP Strong Buy
  • SVCC
  • Analyst Count
  • TNXP 2
  • SVCC 0
  • Target Price
  • TNXP $585.00
  • SVCC N/A
  • AVG Volume (30 Days)
  • TNXP 1.2M
  • SVCC 15.9K
  • Earning Date
  • TNXP 08-15-2025
  • SVCC 01-01-0001
  • Dividend Yield
  • TNXP N/A
  • SVCC N/A
  • EPS Growth
  • TNXP N/A
  • SVCC N/A
  • EPS
  • TNXP N/A
  • SVCC N/A
  • Revenue
  • TNXP $10,041,000.00
  • SVCC N/A
  • Revenue This Year
  • TNXP $22.87
  • SVCC N/A
  • Revenue Next Year
  • TNXP $711.66
  • SVCC N/A
  • P/E Ratio
  • TNXP N/A
  • SVCC N/A
  • Revenue Growth
  • TNXP N/A
  • SVCC N/A
  • 52 Week Low
  • TNXP $6.76
  • SVCC $9.95
  • 52 Week High
  • TNXP $130.00
  • SVCC $10.31
  • Technical
  • Relative Strength Index (RSI)
  • TNXP 70.46
  • SVCC N/A
  • Support Level
  • TNXP $41.64
  • SVCC N/A
  • Resistance Level
  • TNXP $46.00
  • SVCC N/A
  • Average True Range (ATR)
  • TNXP 3.70
  • SVCC 0.00
  • MACD
  • TNXP 0.38
  • SVCC 0.00
  • Stochastic Oscillator
  • TNXP 95.84
  • SVCC 0.00

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

About SVCC Stellar V Capital Corp. Class A Ordinary Shares

Stellar V Capital Corp is a blank check company.

Share on Social Networks: